Personalis Unveils NeXT Personal Dx and Tempus Deal as Shares Tumble 15%

Introduction

Personalis, Inc. (Nasdaq: PSNL) is a biotechnology company based in Fremont, California, specializing in advanced genomics for precision oncology. The company’s assays integrate tumor and normal profiling with proprietary algorithms designed to detect minimal residual disease (MRD) and guide targeted therapy decisions throughout the patient’s care continuum.

Corporate Structure

Founded in 2011, Personalis employs between 201 and 500 staff, encompassing research, development, clinical operations, and commercial functions. The team includes expertise in next-generation sequencing (NGS), immuno-oncology, computational biology, and biomarker strategy. Personalis operates laboratory facilities in California and collaborates with clinical and commercial partners worldwide.

Oncology by Angiola Harry

Recent Developments and News

• October 2025: Personalis launched NeXT Personal Dx, its whole genome-based liquid biopsy laboratory-developed test for MRD detection and cancer recurrence monitoring.
• October 1, 2025: Personalis and Tempus announced a strategic collaboration to co-commercialize NeXT Personal Dx. Under the agreement, Tempus is set to provide up to $12 million in milestone funding, integrate the test into its service menu, and leverage its sales channels to access oncologists. Personalis will handle the processing and billing of tests, support reimbursement efforts, and issue warrants for up to 9.2 million shares of common stock over a period of 24 months.
• June 2025 (ASCO 2025): Two independent studies—PREDICT-DNA and SCANDARE—demonstrated that NeXT Personal Dx exhibited comparable sensitivity in monitoring neoadjuvant triple-negative breast cancer (TNBC), detecting ctDNA signals up to 15 months before conventional imaging techniques.
• November 6, 2025 (upcoming): A live webinar featuring Alan Tan, MD, and Ezra Cohen, MD, will discuss the principles of MRD testing and real-world clinical applications, including surveillance and immunotherapy monitoring. Registration details are available via Personalis and Tempus channels.

Financial and Strategic Analysis

On November 4, 2025, Personalis filed its quarterly 10-Q report, outlining trends in revenue, net income or loss, earnings per share, and cash flow positions. While specific financial figures were not disclosed in the summary, management emphasized ongoing investment in clinical validation and research and development. A Schedule 13D/A amendment filed on September 12, 2025, indicated Tempus AI, Inc. held 14.3 percent of outstanding shares, with Eric Lefkofsky’s aggregate ownership reported at 14.5 percent.

As of market close on November 5, 2025, PSNL shares were priced at $7.40, reflecting a decline of 15.23 percent on a trading volume of 343,448 shares compared to a 30-day average of 11,994 shares. This trading activity appears related to the company's recent announcements and anticipated clinical developments.

Market Position and Industry Context

Personalis operates within the precision oncology diagnostics sector, characterized by rapid evolution in the areas of assay sensitivity, regulatory clearance, and reimbursement dynamics. The company differentiates itself through tumor-informed whole genome approaches and robust tumor-normal comparison algorithms. Collaborations, particularly with Tempus, are intended to enhance market access for lung and breast cancer applications. Industry trends include an increased demand for ultrasensitive ctDNA tests, elevating requirements for clinical validation, and competitive pressures from established diagnostic firms and emerging biotech companies.

tl;dr

Personalis (Nasdaq: PSNL) shares decreased by 15.23 percent to $7.40 on November 5, 2025, with a trading volume of 343,448 shares. In October 2025, the company launched NeXT Personal Dx and established a co-commercialization agreement with Tempus, which includes up to $12 million in milestone funding and warrants for 9.2 million shares. Data presented at ASCO 2025 confirmed the test’s sensitivity in triple-negative breast cancer monitoring. An MRD-focused webinar is scheduled for November 6, 2025. Key drivers include advancements in clinical validation, strategic partnerships, and upcoming regulatory or reimbursement milestones.